

1 **Interleukin 21 is a marker of Human African Trypanosomiasis Infection and a**
2 **contributor to pathology in mice**

3 Paul Capewell¹, Hamidou Ilboudo^{2,3,4}, Anneli Cooper¹, Windingoudi Justin Kaboré², Harry
4 Noyes⁵, Kerry O' Neill¹, Mamadou Camara², Vincent Jamonneau⁴, Annette MacLeod^{1§} and
5 Bruno Bucheton^{2,4§*} for the TrypanoGEN+ research group of the H3Africa consortium

6 *To whom correspondence should be addressed: Bruno BUCHETON bruno.bucheton@ird.fr

7 § joint last authors

8 ¹Wellcome Centre for Integrative Parasitology, College of Medical, Veterinary, and Life
9 Sciences, Henry Wellcome Building for Comparative Medical Sciences, Glasgow, Scotland,
10 United Kingdom.

11 ²Programme National de Lutte Contre la Trypanosomiase Humaine Africaine, Ministère de la
12 Santé, Conakry, Guinea.

13 ³Institut de Recherche en Sciences de la Santé (IRSS)—Unité de Recherche Clinique de
14 Nanoro (URCN), Nanoro, Burkina-Faso.

15 ⁴Institut de Recherche pour le Développement, UMR INTERTRYP IRD-CIRAD, Université de
16 Montpellier, TA A-17/G, Campus International de Baillarguet, 34398 Montpellier, France.

17 ⁵Centre for Genomic Research Biosciences Building, Crown Street Liverpool, United Kingdom.

18

19 **Abstract**

20 **Background:** Human African trypanosomiasis (HAT) is an important disease of sub-Saharan
21 Africa that is approaching elimination in many regions. However, the disease has previously
22 returned from similarly low case numbers in the past, making it important to identify issues that
23 hinder elimination efforts. One important factor is likely to be the recent characterization of
24 individuals with latent HAT infections that are able to tolerate HAT with few symptoms and to

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

25 control blood parasitaemia to levels that are undetectable by microscopy. Although animal
26 trypanotolerance has been examined in detail, it is unclear how the latent phenotype is
27 maintained in humans.

28 **Methods:** To identify immune components involved in latent HAT, we used targeted RNASeq
29 to examine the expression of 495 immune-related transcripts in blood collected from 287
30 individuals at active disease foci in Guinea. These samples included latent infections, HAT
31 clinical cases, and uninfected controls. The *in vivo* effects of IL21 functional blockade was
32 investigated using a murine model of trypanosomiasis.

33 **Results:** Differential expression analysis revealed transcripts involved in T cell activation and B
34 cell development that associated with trypanosome infection, including *PD1*, *CD70*, and *CD80*.
35 In particular, *IL21* was found to be elevated in infected individuals, although it was significantly
36 higher in clinical cases relative to latent infections. This pattern was replicated at the protein
37 level when patient sera were examined by ELISA. Reducing IL21 pathway activity in mice
38 infected with *Trypanosoma brucei* led to increased survivorship and reduced parasitaemia in
39 the model animals.

40 **Conclusion:** Our data show that IL21 is a potential biomarker of Human African
41 Trypanosomiasis and is a cause rather than a consequence of symptoms severity. Further
42 investigation of IL21 will contribute to understanding the factors involved in developing latent
43 HAT, improving control efforts to identify and predict such infections. In the future, the factors
44 identified in this study may also serve as intervention targets to control the symptoms of
45 trypanosomiasis.

46 Introduction

47 Human African trypanosomiasis (HAT) is an important vector-borne disease of sub-Saharan
48 Africa primarily caused by the parasite *Trypanosoma brucei gambiense* (*T. b. gambiense*) [1].
49 The related veterinary disease animal trypanosomiasis (AT) is also a significant economic
50 burden involving a complex of trypanosome species, including *T. congolense*, *T. vivax*, and *T.*

51 *b. brucei* [2]. HAT has been targeted for elimination as a public health problem by 2020 by the
52 World Health Organization (WHO) and reported cases have fallen below 1,000 in recent years
53 [1,3]. The next objective on the HAT control road map is to reach the interruption of transmission
54 by 2030. However, several issues have recently been identified that could hinder these efforts.
55 These include the description of individuals able to tolerate the disease with few symptoms
56 which has overturned of the long-held belief that HAT is invariably fatal. These individuals also
57 display low blood parasitemias and despite positive responses to the serological screening
58 tests, they are generally left untreated by the control programs as the microscopic confirmation
59 of trypanosomes is required in order to initiate treatment [4–8]. These latent infections are
60 initially identified by an elevated response to the card agglutination test for trypanosomiasis
61 (CATT) and then further examined using an immune trypanolysis test targeting the LiTAT1.3
62 Variable Surface Glycoprotein known to be highly specific for *T.b. gambiense* in humans [9].
63 These individuals, termed SERO TL+, are definitively characterised as harbouring a latent
64 infection only if they maintain serological positivity for at least two years without developing
65 symptoms while remaining negative to parasitological tests performed on biological fluids [5,6].
66 During a two-year longitudinal study led in Guinea, 13% of SERO TL+ individuals developed
67 symptoms with detectable parasites (termed SERO TL+/HAT), 48% remained latent [5] and
68 39% became negative to the CATT in a probable process of selfcure [5]. The latent period can
69 be extremely protracted, with one case persisting for 29 years before an unrelated
70 immunosuppressive treatment led to rapid onset of HAT [10]. It has also recently been revealed
71 that African trypanosomes are not exclusively parasites of the blood and can exists in tissues
72 of the host. Most notably, they can colonise the skin where they could act as a significant but
73 overlooked anatomical reservoir [11–13]. Modelling suggests it is likely that these latent
74 infections carry infective parasites and are able to maintain HAT in disease foci without animal
75 reservoirs despite intensive control efforts [14]. This is supported by xenodiagnosis experiments
76 examining asymptomatic people [15] and animals [16] demonstrating that the tsetse vector can
77 be infected by latent hosts and more recently by the detection of trypanosomes in skin biopsies
78 sampled in Guinea from both confirmed HAT patients but also serologically positive individuals

79 that displayed otherwise negative parasitology in blood or lymph [17]. The genotypes of
80 parasites from SERO TL+ individuals are indistinguishable from those infecting clinical cases
81 [7] and genomic analyses of *T. b. gambiense* isolates from across Africa show that the
82 parasite is clonal and highly homogenous [18]. Together, these data suggest that the host is
83 the primary mediator of the differences in symptom severity that can lead to latent infections
84 and SERO TL+ individuals.

85 Investigations of the *APOL1* G1 and G2 polymorphisms within the TrypanoGEN network
86 evidenced a genetic association between the G2 polymorphism and resistance to *T. b.*
87 *rhodesiense* infection [19,20] as well as an increased frequency of G1 carriage in individuals
88 with latent *T. b. gambiense* infections [20][21]. Several immunological studies targeted to
89 specific immune mediators have also revealed differences in the immune response between
90 SERO TL+ and HAT patients. IL8 was elevated in SERO TL+ and in these individuals was
91 predictive of the CATT becoming negative during the follow-up. In addition immunosuppressive
92 molecules such as IL10 and the maternal human leukocyte antigen protein HLA-G were found
93 more elevated in HAT patients and SERO TL+ individuals who subsequently developed the
94 disease [22,23]. However, no causative links between immune factors and latent infections have
95 been demonstrated and the design of earlier studies to decipher the mechanisms of infection
96 resistance/susceptibility in human have had to largely rely on data from studies of
97 trypanotolerant animals. Trypanotolerance has been extensively studied in mice and cattle
98 [24,25], although the majority of such studies have used the animal trypanosome species *T.*
99 *congolense*, *T. vivax*, and *T. b. brucei* rather than *T. b. gambiense*. The term trypanotolerance
100 is also somewhat misleading as these animals do become infected with trypanosomes, develop
101 adverse effects and mount an immune response. Trypanotolerance should rather be
102 understood as reduced pathology and disease in the presence of infection. Despite the different
103 parasite species used, studies of trypanotolerant animals suggest some factors that may affect
104 disease presentation in humans [26]. These include the importance of a strong IFN γ -mediated
105 response early in infection to control the initial peak of parasitaemia, followed by reduction in

106 the IFN γ -mediated inflammatory environment that leads to a long-term and less virulent
107 infection. Key to mediating this environmental shift are the cytokines IL10 and IL4. A robust B
108 cell and humoral response is also required to control the parasite, particularly during the initial
109 peak of parasitaemia [27].

110 To more fully understand the immune components involved in HAT symptom severity and the
111 development of human latent infections, we compared the peripheral blood transcriptomes of
112 *T. b. gambiense* HAT clinical cases, people with latent infections and uninfected controls using
113 a targeted immune transcript analysis. This revealed transcripts involved in T cell activation and
114 B cell development that differed between clinical and latent cases. More specifically, expression
115 of the cytokine *IL21* at both the transcript and protein level associated with symptom severity.
116 Subsequent *in vivo* experiments using functional blockade confirmed that IL21 is involved in
117 determining both symptom severity and parasitaemia during trypanosome infection. This
118 cytokine therefore serves as both a biomarker of trypanosome infection and also offers a new
119 intervention target to limit symptoms of the disease in humans and animals.

120 **Methods**

121 **Study Design**

122 Participants were identified during medical surveys organised by the Guinean National Control
123 Programme (NCP) of HAT from three HAT foci in Guinea (Dubreka, Boffa, and Forecariah)
124 according to the WHO and NCP policies [5,28]. Five mL samples of blood were collected in
125 heparinised tubes from individuals who tested positive for infection using the card agglutination
126 trypanosomiasis test (CATT). A 2-fold dilution series of patient blood was tested to estimate
127 CATT titre. Individuals with titres 1/4 or greater were submitted for microscopic examination of
128 lymph node aspirates and 350 μ L of buffy coat were examined for the presence of trypanosomes
129 using mini-anion exchange centrifugation test (mAECT). If trypanosomes were detected, lumbar
130 puncture was performed, and disease stage determined by identifying trypanosomes and by
131 white blood cell (WBC) counts. Confirmed HAT cases were classified as stage 1 (0–5 WBC/ μ L),

132 early stage 2 (6–20 WBC/ μ L; or \leq 20 WBC with trypanosomes in CSF), or late stage 2 ($>$ 20
133 WBC/ μ L) and treated according to NCP guidelines [28]. For each study individual, 100 μ L of
134 plasma was sampled and 2 mL of blood were taken on PAXgene[®] Blood RNA tubes
135 (PreAnalytiX). All samples were frozen in the field at -20°C in car freezer and were then stored
136 at -80 °C until use. The plasma was used to perform the immune trypanolysis test to detect Litat
137 1.3 and Litat 1.5 variable surface antigens specific for *T. b. gambiense* [9]. The PAXgene[®] blood
138 RNA tubes were used to extract RNA with PAXgene[®] Blood RNA kit (PreAnalytiX). CATT and
139 trypanolysis positive subjects without visible parasites were defined as SERO TL+. SERO TL+
140 individuals were followed-up for at least two years (with an average of three visits) and of these,
141 11 went on to develop HAT and were defined as SERO TL+/HAT. Those that remained CATT
142 and trypanolysis positive for at least two years were defined as having latent infections.

143 **Targeted RNASeq**

144 A Qiagen Human Inflammation & Immunity Transcriptome Kit (RHS-005Z; Qiagen) was used to
145 obtain transcript counts from a panel of 495 genes involved in the innate and acquired immune
146 responses (Supplementary File 1). cDNA libraries were prepared from 56 uninfected controls,
147 168 HAT cases (135 pre- and 33 post-treatment), 36 SERO TL+ samples with latent infections
148 and 11 individuals who were initially CATT and TL positive but parasitologically negative but
149 became parasitologically positive on follow up (SERO/HAT). The resulting Illumina libraries
150 were sequenced on an Illumina NextSeq 500 and filtered and mapped using Qiagen GeneGlobe
151 software (Qiagen). Normalization and pairwise differential expression analysis for each
152 transcript were performed by Qiagen using DESeq2 for R [29] and normalised read counts are
153 provided as Supplementary Data File 4.

154 **IL21 ELISA**

155 A human IL21 ELISA kit (ab119542; Abcam) was used to measure IL21 titres in sera from eight
156 samples randomly selected from each group (Control, HAT, SERO TL+, and SERO/HAT)
157 following the manufacturer's instructions. There were three replicates for each sample.

158 **Anti-IL21 intervention**

159 To assess the effects of reducing IL21 pathway function *in vivo*, 8-week-old female BALB/c mice
160 were housed in a specific pathogen-free environment in accordance with local and Home Office
161 regulations. Two experiments were performed using four mice treated with 100 µg recombinant
162 anti-IL21 neutralizing antibody every other day from day -1 (FFA21; Thermo Fisher Scientific).
163 These concentrations were selected based on previous *in vivo* studies examining the role of
164 IL21 during viral infection [30]. In addition, four mice per experiment were injected with 100 µg
165 isotype antibody on the same days to serve as controls (Rat IgG2a κ; Thermo Fisher Scientific).
166 All mice were inoculated intraperitoneally with 10⁴ STIB247 *T. b. brucei* parasites on day 0 and
167 parasitaemia was assayed on each subsequent day using phase microscopy [31].

168


169 **Results**

170 **Targeted RNASeq**


171 In order to identify potential differentiators between infected individuals (both SERO TL+ and
172 HAT) and controls, in addition to clinical cases and latent individuals, a cost-effective targeted
173 RNASeq approach was used to examine 495 immune-related genes in whole blood RNA
174 purified from 271 individuals from active disease foci in Guinea. The targeted genes encompass
175 various canonical B cell and T cell pathways (Supplementary File 1). The sample library
176 included uninfected controls (n = 56); HAT cases pre-treatment (n = 135); post-treatment HAT
177 cases (n = 33); latent infections (SERO TL+ individuals who had remained serology positive
178 and parasitologically negative for two years) (n = 36) and SERO/HAT (individuals who were
179 seropositive but parasitologically negative at first screening but became parasitologically
180 positive at a later screening) (n = 11). Normalised read counts for all genes and participants are
181 available in Supplementary data file 4. The expression profiles of these groups were then
182 compared pairwise to reveal differentially expressed transcripts (Supplementary 3; Figure 1). In
183 a comparison of HAT cases versus controls, 10 transcripts were found to be differentially

184 regulated with an FDR $p_{\text{adj}} < 0.001$ (Figure 1A). Expression of the high affinity IgE receptor
185 *FCER1A* was lower in HAT cases, but the expression levels of *IL21*, *CD1C*, *TLR10*, *IL12B*, *PD1*,
186 *CD70*, *CD80*, *CAV1*, and *MET* were all higher. No significant differences were found between
187 HAT cases post-treatment and controls, although a comparison of HAT cases pre- and post-
188 treatment revealed that the expression levels of *IL21*, *CD1C*, *IL10*, *IL12B*, *CAV1*, and *MET* were
189 all significantly higher in the pre-treatment group ($p_{\text{adj}} < 0.001$; Figure 1B). A comparison of
190 individuals with latent infections versus controls found only two transcripts that differed
191 significantly in expression (*IL21* and *IL12B*) with $p_{\text{adj}} < 0.001$ (Figure 1C). Both of these
192 transcripts were also significant in the HAT versus control comparison. Finally, a comparison of
193 individuals with latent infections and HAT clinical cases found four transcripts that showed
194 significant differences in expression (*CD1C*, *IL21*, *CAV1*, and *MET*) with $p_{\text{adj}} < 0.001$ (Figure
195 1D). Again, these transcripts were significant in the HAT clinical cases versus control
196 comparison. It was noted that *IL21* was significant across multiple comparisons and elevated in
197 both HAT and latent infection groups. However, expression was significantly higher in the
198 clinical HAT group relative to the latent infection cohort, suggesting it may be involved in the
199 development of HAT symptoms. To establish if the pattern observed in *IL21* transcript
200 expression correlated with the protein level, an anti-IL21 ELISA was performed using sera from
201 a subset of samples from each group ($n = 8$ for each group). This confirmed that the pattern of
202 IL21 expression at the protein level was the same as the transcript level, being elevated in
203 infected individuals but much higher in clinical HAT (Figure 2). Finally, to assess if IL21 levels
204 may be predictive for SERO TL+ individuals that go on to develop HAT, titres from the 11
205 SERO/HAT individuals were also examined. These samples were taken from patients that were
206 serologically positive without symptoms but went on to develop disease with detectable
207 parasitaemia during the two-year follow-up period. This differs from the SERO TL+ group that
208 maintained their latent phenotype with undetectable parasitaemia. IL21 titres in the SERO/HAT
209 group that progressed to active disease were not found to be significantly different from SERO
210 TL+ individuals that maintained their latent phenotype for the duration of the study, suggesting
211 that elevated IL21 is associated with infection rather than acting as a predictive marker of risk

212 of developing active disease. Nevertheless, these data reveal that *IL21* transcript and IL21
213 protein are elevated during trypanosome infection and are higher in clinical HAT cases relative
214 to latent SERO TL+ infections.



215
216 **Figure 1. Genes with differential expression between latent infections, HAT, and Control**
217 **groups.** Volcano plots demonstrating the relationships between $-\log_{10}(p_{adj} \text{ values})$ and the
218 \log_2 fold change values obtained from DESeq2. Genes showing differential expression with a
219 p_{adj} value above 0.05 and \log_2 fold change ≤ -1 or ≥ 1 are coloured red (up-regulated) or blue
220 (down-regulated). The panels show significant genes identified in comparisons between (A)
221 clinical HAT cases versus controls, (B) clinical HAT cases versus HAT post-treatment, (C)
222 individuals with latent infections versus controls, and (D) individuals with latent infections versus
223 HAT cases.



224


225

226 **Figure 2. Serum IL21 Titres and mRNA expression show that both protein and mRNA**
227 **levels increase after infection . (A)** IL21 titres were assessed by ELISA for a random subset
228 of control, latent infections (SERO TL+), individuals with HAT and those who have developed
229 active HAT after first presenting with just positive serology (SERO/HAT). Sera were from the
230 targeted RNASeq study (n = 8 per group). There was a significant difference between both
231 SERO TL+ and SERO/HAT individuals and HAT patients (T-Test, $p < 0.01$) but no difference
232 between SERO TL+ and SERO/HAT individuals (T test, $p = 0.90$). **(B)** IL21 mRNA from the
233 targeted RNAseq data representing the same groups.

234 **IL21 Functional Intervention**

235 To establish whether IL21 was a cause or consequence of HAT severity, the IL21 pathway was
236 inhibited using a neutralising anti-IL21 antibody in a HAT mouse model across two trials
237 (parasitaemia data are presented in Supplementary File 2). During the first trial, one animal in
238 the control group treated with isotype control succumbed to trypanosomiasis at day eight and
239 the remaining controls were euthanized due to severe illness. All of the mice in the experimental
240 group treated with the neutralising antibody were healthy and presented with no symptoms,
241 although they were also euthanized due to the terms of the license under which the work was
242 performed. During the second trial, the experiment was again curtailed at day eight due to
243 severe symptom and paralysis in the control group. As in the previous experiment all of the mice

244 treated with anti-IL21 antibody were visibly healthy. This suggests that the IL21 pathway is
245 involved in increased symptom severity during trypanosome infection rather than being simply
246 a consequence of symptom development. However, the early end of these experiment means
247 further work is required to fully understand the mechanisms involved. In addition, when the
248 parasitaemia curves from the two independent experiments were aligned to the first peak of
249 parasitaemia, a significant interaction effect was observed between treatment and day (ANOVA,
250 $F = 3.02$, $p < 0.01$). An interaction effect represents the combined effects of factors on the
251 dependent measure (parasitaemia), with the impact of one factor depending on the level of
252 another factor. In this case, the effect of the neutralising anti-IL21 antibody on parasitaemia
253 depended on days post-infection (Figure 3). When days were examined individually, there was
254 a significant difference observed in the magnitude of the first peak of parasitaemia between
255 treated and control groups (T Test, $p = 0.03$). These data show that administration of the anti-
256 IL21 antibody affected parasite number in addition to affecting symptoms, demonstrating that
257 IL21 has a significant impact on parasitaemia and symptom severity during African trypanosome
258 infections. In particular, reducing IL21 pathway function associates with better outcomes and
259 lower parasitaemia.



260

261 **Figure 3. The effect of IL21 functional blockade on parasitaemia in a HAT model.** Eight
262 mice were infected with *T. b. brucei* STIB247 across two different experiments. Mice were
263 administered with a blocking anti-IL21 chimera antibody (red line) or an isotype control (blue
264 line) on alternate days beginning the day before inoculation. Parasitaemia was estimated daily
265 via microscopy and the resulting curves were aligned to the first peak (day 0) to account for
266 individual variation. Blocking IL21 consistently reduced parasitaemia. Mean parasitaemia for
267 treatment and isotype control are shown with 95% confidence intervals. A significant interaction
268 effect was observed between treatment and days post-infection (ANOVA, $p < 0.01$) and there
269 was a significant difference observed in size of the first parasitaemia peak (T Test, $p = 0.03$).

270

271 **Discussion**

272 As HAT approaches elimination, it becomes increasingly important to identify and understand
273 factors that may impact the control of this deadly parasite, particularly latent infections, and the
274 role of the skin as an anatomical reservoir [3,32]. Our study used RNASeq on a panel of 496
275 genes involved in the innate and acquired immune responses to identify immune components
276 involved in the latent phenotype in 260 individuals from HAT active foci in Guinea. When
277 comparing HAT cases and controls, we identified 10 transcripts that associate with clinical
278 disease, some of which have never previously been identified as being involved in HAT. These
279 included transcripts for *IL21*, *IL12B*, *IL10*, *CD1C*, *TLR10*, *PD1*, *CD70*, *CD80*, *CAV1*, and *MET*.
280 Interleukin-12 subunit beta (IL12B) is a component of IL12, a cytokine involved in a wide range
281 of immune responses during infectious challenge [33,34]. However, the subunit is also a
282 component of IL23, and our data is unable to assign this increase in *IL12B* expression to IL12,
283 IL23, or both. However, IL23 is an important mediator of Th17-mediated and GM-CSF
284 responses involved in controlling extracellular parasites [35]. Many of the protective roles
285 assigned to IL12 are now also being reassessed in light of the description of IL23 [36]. Further
286 work is therefore required to establish whether IL23 expression is important during African
287 trypanosome infection and to establish the role of Th17 responses. Transcripts involved in T

288 cell activation and exhaustion were also identified, including *PD1* and *CD70* (both immune
289 checkpoint markers), and *CD80* (a receptor for the co-stimulatory protein CD28). The
290 involvement of T cell activation and co-stimulation imply that increased T cell activation is
291 occurring in infected individuals, likely in response to the presence of a pathogen. However, it
292 has also been suggested that African trypanosomes possess a lymphocyte triggering factor
293 (TLTF) that drives polyclonal (non-specific) T activation [37,38], leading to higher expression of
294 proteins associating with immune exhaustion and suppression. PD1, highlighted in our study, is
295 one such suppressive protein that acts via its ligands (PDL1 and PDL2) to down-regulate the
296 immune system and promote self-tolerance [39]. Although PD1 has not previously been
297 associated with trypanosome infection, the pathway has been implicated in the response and
298 control of several important parasites, including *Toxoplasma*, *Leishmania*, and *Plasmodium*
299 [40–42]. Both PD1 and IL10 were elevated in HAT cases and they co-operate to suppress CD8+
300 Tcells [43]. Severe immune suppression is a classically described feature of African
301 trypanosome infection in humans and livestock [44][45] and we hypothesize that this may be
302 due to increased activation of IL10 and the PD1 pathway in infected hosts. Further investigation
303 is required to establish if this is the case and whether intervention can alleviate immune
304 suppression and improve symptoms, as shown for *Plasmodium* [41] and *Leishmania donovani*
305 [42].

306 Very little is known about Toll-like receptor 10 (TLR10) as mice do not possess the protein,
307 limiting investigation [46]. However, unlike all other TLRs, it is immune suppressive and may
308 therefore be involved in the systemic immune suppression seen during trypanosome infections
309 [47]. Our data indicate that African trypanosomes may serve as a powerful model system to
310 elucidate some of the mechanisms of these understudied immune proteins. Finally, our
311 comparison between HAT cases and controls revealed that the high affinity IgE receptor
312 *FCER1A* showed lower expression in infected patients. Previously it has been shown in
313 trypanosome-infected rats that there is a reduced anaphylaxis due to parasite-mediated
314 disruption of IgE-specific pathways [48]. Our data suggest a similar effect may occur in humans

315 and that lowered expression of *FCER1A* may contribute to a decrease in IgE responses. It is
316 unclear why African trypanosomes would target these anaphylactic pathways, but it may be
317 related to controlling the immune response in the skin. Previous data has shown that there is
318 almost no inflammatory reaction to trypanosomes present in the skin of infected mice, despite
319 high parasite burdens [12]. Finally, our data show that after treatment, the expression of these
320 transcripts, including immune suppressive transcripts such as *PD1*, return to levels equivalent
321 to controls. This suggests that the perturbation to a patient's immune system is not permanent.
322 A similar effect has been observed in the immune systems of HAT patients that have been
323 previously examined [49].

324 Across each of the targeted RNASeq comparisons, *IL21* has emerged as a recurring factor that
325 was highlighted as elevated in both HAT cases and latent infections versus controls. However,
326 *IL21* transcript levels were lower in latent cases when compared to HAT patients. This suggests
327 that *IL21* is elevated during trypanosome infection but is significantly higher in clinical cases.
328 This pattern was confirmed at the protein level by ELISA. Our subsequent *in vivo* intervention
329 using a mouse model of HAT has confirmed that reducing the activity of the IL21 pathway
330 through functional blockade leads to higher survival rates and reduced parasitaemia in infected
331 animals. This demonstrates that *IL21* expression influences the severity of symptoms rather
332 than elevated expression simply being a consequence of African trypanosome infection. In
333 contrast blockade of IL21 or IL21R in mice infected with *Plasmodium chabaudi* lead to sustained
334 high parasitaemia and a failure to resolve the chronic stage of the infection [50]. IL21 is a
335 pleiotropic cytokine with a wide range of interactions across immune and non-immune cell types
336 [51]. It is primarily made by activated T cells, particularly T follicular helper (Tfh cells), and one
337 of its primary functions is to promote B cell development and maintain humoral responses [52].
338 Patients with defective IL21 signalling are severely immune compromised, suffering from
339 deficiencies in plasma cell and memory B cell generation, as well as immunoglobulin class
340 switching [53–55]. They also suffer from repeated secondary infections due to increased
341 susceptibility to infection [54]. However, IL21 has been described as a “double-edged sword”

342 due to a complicated role in immunity, either supporting and suppressing B cell development
343 depending on serum levels and interactions with other cytokines present [51][56]. In particular,
344 IL21 has a potent immunosuppressive effect at high serum titres, primarily through Tfh driving
345 cell cycle arrest and apoptosis in B cells [57–59]. Interestingly, destruction of the B cell
346 compartment is a distinctive component of African trypanosome infection in mice [60], although
347 this effect may be less pronounced during more chronic *T. b. gambiense* infections [61].
348 Nevertheless, our data suggest that disruption of the B cell population in mice may be due to
349 elevated IL21 levels and further experimentation is required to confirm this hypothesis. Although
350 we did not observe a decrease in B cell numbers during our *in vivo* experiments (data not
351 shown), these data were collected on day eight and B cell destruction was not noticeable until
352 after day 10 in previous studies [60].

353 Based on our data, we hypothesize that a perturbation in T cell activation and B cell
354 development contributes to immune suppression, higher parasitaemia, and the development of
355 symptoms in clinical HAT cases. IL21 appears intimately involved in these affects and our data
356 suggest that latent infections with reduced symptoms are in some part due to the control of this
357 cytokine. As IL21 is primarily produced by activated T cells, reducing activation would lead to
358 less activity in the IL21 pathway, maintaining a robust B cell and humoral response. In a previous
359 study that examined trypanosome-mediated polyclonal T cell activation in susceptible and
360 resistance mice, more resistant strains differed in their response to the polyclonal activator TLTF
361 by increasing expression of cytokines associated with antibody synthesis and class switching
362 [62]. While this supports our hypothesis, much more investigation is required to establish which
363 cell populations are expressing IL21 and whether blockade of activation checkpoint proteins
364 (such as PD1) can alleviate symptoms in an animal model of HAT. In *Plasmodium* infections,
365 polyclonal T cell activation caused by the parasite leads to elevated expression of PD1 on Tfh
366 cells, again leading to impaired B cell and humoral responses. When PD1-mediated
367 suppression is alleviated via blocking antibodies (alongside blockade of another checkpoint
368 marker LAG3), Tfh function and B cell responses are restored, resulting in less severe

369 symptoms [41]. It is possible that a similar effect is occurring during HAT, with individuals with
370 latent infections displaying less activation and exhaustion in the Tfh population, maintaining B
371 cell and humoral responses, leading to a long term control of parasitaemia but not parasite
372 elimination. This would suggest that IL21 and PD1 are potential intervention targets that may
373 play a role in controlling symptoms by maintaining the strength of the host immune system,
374 particularly in livestock where the elimination of trypanosomiasis is unlikely if not impossible.

375 In addition, of its potential functional role in mediating *T. b. gambiense* infection outcomes, IL21
376 also appears as an interesting biomarker of trypanosome infection in human. With the upcoming
377 availability of new oral drugs, in particular Acoziborol given as a single dose, the treatment of
378 individuals testing positive to the actual serological tests (CATT or RDTs) is likely to become a
379 reality in the coming years if the drug is proved to be safe enough [63,64]. A major challenge of
380 this largely simplified test and treat strategy reside in the fact that all the actual antibody
381 detection tests for HAT lack specificity and in low endemic prevalence contexts display poor
382 positive predictive values [65]. Detection of IL21 in a simple test format in those serological
383 suspects is likely to enhance the identification of individuals with active infections thus reducing
384 considerably the number of “unnecessary” treatments. The fact that the plasma levels of IL21
385 were shown to be significantly higher in both latent and HAT patients as compared to controls
386 is a proof of concept that it is a reachable goal. Larger multi-centric studies integrating other co-
387 infections as potential confounding factors will be required to further validate IL21 as a
388 biomarker *T. b. gambiense* infection in humans.

389 **Conclusion**

390 Our study is an example of successfully applying targeted transcriptomics to identify genes
391 associating with latent carriage of HAT, highlighting IL21 as a potential biomarker of infection
392 as well as a key mediator of symptom severity and a likely contributor to the development of a
393 latent phenotype. Importantly, we have used an animal model to confirm the relevance of IL21
394 during African trypanosome infections. Further investigation of IL21, and its role in disease, will
395 improve our understanding of the factors involved in developing clinical HAT or latent infections,

396 but may also contribute to the development of more productive and trypanosome tolerant
397 livestock breeds.

398 **Declarations**

399 **Ethics approval and consent to participate**

400 All investigations on humans were conducted in accordance with the Declaration of Helsinki.
401 Participants were identified through healthcare providers, community engagement and active
402 surveillance campaigns led by the national control program, Ministry of Health Guinea. Written
403 informed consents for sample collection, analysis and publication of anonymised data was
404 obtained from all participants by trained local healthcare workers. Subjects or their legal
405 guardian gave consent as a signature or a thumbprint after receiving standardized information
406 in French or their local language as preferred. Ethical approvals for the study was obtained from
407 within the TrypanoGEN Project following H3Africa Consortium guidelines for informed consent
408 [66] and from Comité Consultatif de Déontologie et d'éthique (CCDE) at the Institut de recherche
409 pour le Développement (IRD; 10/06/2013). Research procedures were also approved by the
410 University of Glasgow MVLS Ethics Committee for Non-Clinical Research Involving Human
411 Subjects (Reference no. 200120043).

412 All animal experiments were approved by the University of Glasgow Ethical Review Committee
413 and performed in accordance with the UK Home Office guidelines, UK Animals (Scientific
414 Procedures) Act, 1986 and EU directive 2010/63/EU. All experiments were conducted under
415 SAPO regulations and UK Home Office project licence number PC8C3B25C to Dr. Jean
416 Rodgers.

417 **Competing interests**

418 The authors declare that they have no competing interests

419 **Funding**

420 PC, AC, AML were funded by a Wellcome Senior Fellowship to AML (209511/Z/17/Z). BB was
421 funded by IRD. WJK, HN and HI, were supported through the Human Hereditary and Health in
422 Africa (H3Africa) [H3A/18/004]. The second phase of the Wellcome component of H3Africa is
423 being implemented by the African Academy of Sciences (AAS) and the NEPAD Agency's
424 Alliance for Accelerating Excellence in Science in Africa (AESA) in partnership with Wellcome.

425 **Authors' contributions**

426 PC conducted in vitro and vivo experiments drafted manuscript; AC conducted in vitro and in
427 vivo experiments; WJK Sample Collection and RNA prep revised manuscript; HI Sample
428 Collection and RNA prep; HN Revised manuscript; KO'N In vivo experiments; MC, VJ
429 Managed and participated in sample collection; AM and BB Devised experiment and revised
430 manuscript.

431 **Acknowledgements**

432 The authors would like to acknowledge the study participants who donated their specimens,
433 the personnel involved in the community engagement and coordinating sample collection and
434 processing, the national sleeping sickness control programmes of the participating countries.
435 The views expressed in this publication are those of the author(s) and not necessarily those of
436 AAS, the NEPAD Agency nor Wellcome.

437

438 **References**

- 439 1. WHO. Trypanosomiasis, human African (sleeping sickness). 2020 [cited 20 Apr 2022] p. WHO
440 Fact Sheet, No. 259. Available: [https://www.who.int/news-room/fact-](https://www.who.int/news-room/fact-sheets/detail/trypanosomiasis-human-african-(sleeping-sickness))
441 [sheets/detail/trypanosomiasis-human-african-\(sleeping-sickness\)](https://www.who.int/news-room/fact-sheets/detail/trypanosomiasis-human-african-(sleeping-sickness))
- 442 2. Kristjanson PM, Swallow BM, Rowlands GJ, Kruska RL, De Leeuw PN. Measuring the costs of
443 African animal trypanosomosis, the potential benefits of control and returns to research.
444 *Agricultural Systems*. 1999;59: 79–98. doi:10.1016/S0308-521X(98)00086-9
- 445 3. Akazue PI, Ebiloma GU, Ajibola O, Isaac C, Onyekwelu K, Ezeh CO, et al. Sustainable Elimination
446 (Zero Cases) of Sleeping Sickness: How Far Are We from Achieving This Goal? *Pathogens* 2019,
447 Vol 8, Page 135. 2019;8: 135. doi:10.3390/PATHOGENS8030135

- 448 4. Ilboudo H, Bras-Goncalves R, Camara M, Flori L, Camara O, Sakande H, et al. Unravelling human
449 trypanotolerance: IL8 is associated with infection control whereas IL10 and TNFalpha are
450 associated with subsequent disease development. *PLoS Pathog.* 2014;10: e1004469.
451 doi:10.1371/journal.ppat.1004469
- 452 5. Ilboudo H, Jamonneau V, Camara M, Camara O, Dama E, Léno M, et al. Diversity of response to
453 *Trypanosoma brucei gambiense* infections in the Forecariah mangrove focus (Guinea):
454 Perspectives for a better control of sleeping sickness. *Microbes and Infection.* 2011.
455 doi:10.1016/j.micinf.2011.05.007
- 456 6. Jamonneau V, Ilboudo H, Kaboré J, Kaba D, Koffi M, Solano P, et al. Untreated Human Infections
457 by *Trypanosoma brucei gambiense* are Not 100% Fatal. *PLoS Negl Trop Dis.* 2012.
458 doi:10.1371/journal.pntd.0001691
- 459 7. Kabore J, Koffi M, Bucheton B, MacLeod A, Duffy C, Ilboudo H, et al. First evidence that parasite
460 infecting apparent aparasitemic serological suspects in human African trypanosomiasis are
461 *Trypanosoma brucei gambiense* and are similar to those found in patients. *Infect Genet Evol.*
462 2011;11: 1250–1255. doi:10.1016/j.meegid.2011.04.014
- 463 8. Koffi M, Solano P, Denizot M, Courtin D, Garcia A, Lejon V, et al. Aparasitemic serological
464 suspects in *Trypanosoma brucei gambiense* human African trypanosomiasis: a potential human
465 reservoir of parasites? *Acta Trop.* 2006;98: 183–188. doi:10.1016/j.actatropica.2006.04.001
- 466 9. Jamonneau V, Bucheton B, Kaboré J, Ilboudo H, Camara O, Courtin F, et al. Revisiting the immune
467 trypanolysis test to optimise epidemiological surveillance and control of sleeping sickness in
468 West Africa. *PLoS Neglected Tropical Diseases.* 2010. doi:10.1371/journal.pntd.0000917
- 469 10. Sudarshi D, Lawrence S, Pickrell WO, Eligar V, Walters R, Quaderi S, et al. Human African
470 Trypanosomiasis Presenting at Least 29 Years after Infection—What Can This Teach Us about the
471 Pathogenesis and Control of This Neglected Tropical Disease? *PLOS Neglected Tropical Diseases.*
472 2014;8: e3349. doi:10.1371/JOURNAL.PNTD.0003349
- 473 11. Caljon G, Van Reet N, De Trez C, Vermeersch M, Pérez-Morga D, Van Den Abbeele J. The Dermis
474 as a Delivery Site of *Trypanosoma brucei* for Tsetse Flies. *PLOS Pathogens.* 2016;12: e1005744.
475 doi:10.1371/JOURNAL.PPAT.1005744
- 476 12. Capewell P, Cren-Travaille C, Marchesi F, Johnston P, Clucas C, Benson RA, et al. The skin is a
477 significant but overlooked anatomical reservoir for vector-borne African trypanosomes. *eLife.*
478 2016;5. doi:10.7554/eLife.17716
- 479 13. Trindade S, Rijo-Ferreira F, Carvalho T, Pinto-Neves D, Guegan F, Aresta-Branco F, et al.
480 *Trypanosoma brucei* Parasites Occupy and Functionally Adapt to the Adipose Tissue in Mice. *Cell*
481 *host & microbe.* 2016;19: 837–848. doi:10.1016/J.CHOM.2016.05.002
- 482 14. Capewell P, Atkins K, Weir W, Jamonneau V, Camara M, Clucas C, et al. Resolving the apparent
483 transmission paradox of African sleeping sickness. *PLOS Biology.* 2019;17: e3000105.
484 doi:10.1371/JOURNAL.PBIO.3000105
- 485 15. Frezil JL. Application of xenodiagnosis for the demonstration of *T. gambiense* trypanosomiasis in
486 immunologically suspect individuals. In: *Bulletin de la Société de Pathologie Exotique* [Internet].
487 1971 [cited 20 Apr 2022] p. 64: 871-878. Available:
488 <https://www.cabdirect.org/cabdirect/abstract/19732900264>

- 489 16. Wombou Toukam CM, Solano P, Bengaly Z, Jamonneau V, Bucheton B. Experimental evaluation
490 of xenodiagnosis to detect trypanosomes at low parasitaemia levels in infected hosts. *Parasite*
491 (Paris, France). 2011;18: 295–302. doi:10.1051/PARASITE/2011184295
- 492 17. Camara M, Soumah AM, Ilboudo H, Travaille C, Clucas C, Cooper A, et al. Extravascular Dermal
493 Trypanosomes in Suspected and Confirmed Cases of gambiense Human African Trypanosomiasis.
494 *Clinical Infectious Diseases*. 2021;73: 12–20. doi:10.1093/cid/ciaa897
- 495 18. Weir W, Capewell P, Foth B, Clucas C, Pountain A, Steketee P, et al. Population genomics reveals
496 the origin and asexual evolution of human infective trypanosomes. *eLife*. 2016;5.
497 doi:10.7554/ELIFE.11473
- 498 19. Kamoto K, Noyes H, Nambala P, Senga E, Musaya J, Kumwenda B, et al. Association of APOL1
499 renal disease risk alleles with *Trypanosoma brucei rhodesiense* infection outcomes in the
500 northern part of Malawi. *PLOS Neglected Tropical Diseases*. 2019;13: e0007603.
501 doi:10.1371/journal.pntd.0007603
- 502 20. Cooper A, Ilboudo H, Alibu VP, Ravel S, Enyaru J, Weir W, et al. APOL1 renal risk variants have
503 contrasting resistance and susceptibility associations with African trypanosomiasis. Tishkoff S,
504 editor. *eLife*. 2017;6: e25461. doi:10.7554/eLife.25461
- 505 21. Kaboré JW, Ilboudo H, Noyes H, Camara O, Kaboré J, Camara M, et al. Candidate gene
506 polymorphisms study between human African trypanosomiasis clinical phenotypes in Guinea.
507 *PLOS Neglected Tropical Diseases*. 2017;11: e0005833. doi:10.1371/journal.pntd.0005833
- 508 22. Courtin D, Milet J, Sabbagh A, Massaro JD, Castelli EC, Jamonneau V, et al. HLA-G 3' UTR-2
509 haplotype is associated with Human African trypanosomiasis susceptibility. *Infection, Genetics*
510 *and Evolution*. 2013. doi:10.1016/j.meegid.2013.03.004
- 511 23. Gineau L, Courtin D, Camara M, Ilboudo H, Jamonneau V, Dias FC, et al. Human Leukocyte
512 Antigen-G: A Promising Prognostic Marker of Disease Progression to Improve the Control of
513 Human African Trypanosomiasis. *Clinical Infectious Diseases*. 2016. doi:10.1093/cid/ciw505
- 514 24. Courtin D, Berthier D, Thevenon S, Dayo GK, Garcia A, Bucheton B. Host genetics in African
515 trypanosomiasis. *Infect Genet Evol*. 2008;8: 229–238. doi:10.1016/j.meegid.2008.02.007
- 516 25. Kemp SJ, Darvasi A, Soller M, Teale AJ. Genetic control of resistance to trypanosomiasis.
517 *Veterinary immunology and immunopathology*. 1996;54: 239–243. doi:10.1016/S0165-
518 2427(96)05692-9
- 519 26. Mansfield JM, Paulnock DM. Regulation of innate and acquired immunity in African
520 trypanosomiasis. *Parasite immunology*. 2005;27: 361–371. doi:10.1111/J.1365-
521 3024.2005.00791.X
- 522 27. Magez S, Schwegmann A, Atkinson R, Claes F, Drennan M, De Baetselier P, et al. The role of B-
523 cells and IgM antibodies in parasitemia, anemia, and VSG switching in *Trypanosoma brucei*-
524 infected mice. *PLoS pathogens*. 2008;4. doi:10.1371/JOURNAL.PPAT.1000122
- 525 28. Camara M, Kaba D, KagbaDouno M, Sanon JR, Ouendeno FF, Solano P. [Human African
526 trypanosomiasis in the mangrove forest in Guinea: epidemiological and clinical features in two
527 adjacent outbreak areas]. *Med Trop (Mars)*. 2005;65: 155–161.

- 528 29. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq
529 data with DESeq2. *Genome Biology*. 2014;15: 550. doi:10.1186/s13059-014-0550-8
- 530 30. Shen Z, Yang H, Yang S, Wang W, Cui X, Zhou X, et al. Hepatitis B virus persistence in mice reveals
531 IL-21 and IL-33 as regulators of viral clearance. *Nature communications*. 2017;8.
532 doi:10.1038/S41467-017-02304-7
- 533 31. Herbert WJ, Lumsden WHR. *Trypanosoma brucei*: a rapid “matching” method for estimating the
534 host’s parasitemia. *Experimental parasitology*. 1976;40: 427–431. doi:10.1016/0014-
535 4894(76)90110-7
- 536 32. Berthier D, Brenière SF, Bras-Gonçalves R, Lemesre JL, Jamonneau V, Solano P, et al. Tolerance to
537 Trypanosomatids: A Threat, or a Key for Disease Elimination? *Trends in parasitology*. 2016;32:
538 157–168. doi:10.1016/J.PT.2015.11.001
- 539 33. Dorman SE, Holland SM. Interferon-gamma and interleukin-12 pathway defects and human
540 disease. *Cytokine & growth factor reviews*. 2000;11: 321–333. doi:10.1016/S1359-
541 6101(00)00010-1
- 542 34. Locksley RM. Interleukin 12 in host defense against microbial pathogens. *Proceedings of the*
543 *National Academy of Sciences of the United States of America*. 1993;90: 5879–5880.
544 doi:10.1073/PNAS.90.13.5879
- 545 35. Tang C, Chen S, Qian H, Huang W. Interleukin-23: as a drug target for autoimmune inflammatory
546 diseases. *Immunology*. 2012;135: 112–124. doi:10.1111/J.1365-2567.2011.03522.X
- 547 36. Cua DJ, Sherlock J, Chen Y, Murphy CA, Joyce B, Seymour B, et al. Interleukin-23 rather than
548 interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. *Nature*.
549 2003;421: 744–748. doi:10.1038/NATURE01355
- 550 37. Abdulla MH, Bakhiet M, Lejon V, Andersson J, McKerrow J, Al-Obeed O, et al. TLTF in
551 cerebrospinal fluid for detection and staging of *T. b. gambiense* infection. *PloS one*. 2013;8.
552 doi:10.1371/JOURNAL.PONE.0079281
- 553 38. BAKHIET M, OLSSON T, EDLUND C, HÖJEBERG B, HOLMBERG K, LORENTZHN J, et al. A
554 *Trypanosoma brucei* brucei-derived factor that triggers CD8+ lymphocytes to interferon-gamma
555 secretion: purification, characterization and protective effects in vivo by treatment with a
556 monoclonal antibody against the factor. *Scandinavian journal of immunology*. 1993;37: 165–178.
557 doi:10.1111/J.1365-3083.1993.TB01753.X
- 558 39. Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity.
559 *Immunological reviews*. 2010;236: 219–242. doi:10.1111/J.1600-065X.2010.00923.X
- 560 40. Bhadra R, Gigley JP, Weiss LM, Khan IA. Control of *Toxoplasma* reactivation by rescue of
561 dysfunctional CD8+ T-cell response via PD-1-PDL-1 blockade. *Proceedings of the National*
562 *Academy of Sciences of the United States of America*. 2011;108: 9196–9201.
563 doi:10.1073/PNAS.1015298108
- 564 41. Butler NS, Moebius J, Pewe LL, Traore B, Doumbo OK, Tygrett LT, et al. Therapeutic blockade of
565 PD-L1 and LAG-3 rapidly clears established blood-stage *Plasmodium* infection. *Nature*
566 *immunology*. 2011;13: 188–195. doi:10.1038/NI.2180

- 567 42. Habib S, El Andaloussi A, Elmasry K, Handoussa A, Azab M, Elsayey A, et al. PDL-1 Blockade
568 Prevents T Cell Exhaustion, Inhibits Autophagy, and Promotes Clearance of *Leishmania donovani*.
569 *Infection and immunity*. 2018;86. doi:10.1128/IAI.00019-18
- 570 43. Sun Z, Fourcade J, Pagliano O, Chauvin J-M, Sander C, Kirkwood JM, et al. IL10 and PD-1
571 Cooperate to Limit the Activity of Tumor-Specific CD8+ T Cells. *Cancer Research*. 2015;75: 1635–
572 1644. doi:10.1158/0008-5472.CAN-14-3016
- 573 44. Roelants GE, Pinder M. Immunobiology of African trypanosomiasis. *Contemporary topics in*
574 *immunobiology*. 1984;12: 225–274. doi:10.1007/978-1-4684-4571-8_7
- 575 45. Marañón C. Whole genome transcriptome reveals metabolic and immune susceptibility factors
576 for *Trypanosoma congolense* infection in West-African livestock. *PCI Infections*. 2023; 100008.
577 doi:10.24072/pci.infections.100008
- 578 46. Chuang TH, Ulevitch RJ. Identification of hTLR10: a novel human Toll-like receptor preferentially
579 expressed in immune cells. *Biochimica et biophysica acta*. 2001;1518: 157–161.
580 doi:10.1016/S0167-4781(00)00289-X
- 581 47. Hess NJ, Jiang S, Li X, Guan Y, Tapping RI. TLR10 Is a B Cell Intrinsic Suppressor of Adaptive
582 Immune Responses. *Journal of immunology (Baltimore, Md : 1950)*. 2017;198: 699–707.
583 doi:10.4049/JIMMUNOL.1601335
- 584 48. Gould SS, Castro GA. Suppression by *Trypanosoma brucei* of anaphylaxis-mediated ion transport
585 in the small intestine of rats. *Immunology*. 1994/03/01 ed. 1994;81: 468.
- 586 49. Lejon V, Mumba Ngoyi D, Kestens L, Boel L, Barbé B, Kande Betu V, et al. Gambiense Human
587 African Trypanosomiasis and Immunological Memory: Effect on Phenotypic Lymphocyte Profiles
588 and Humoral Immunity. *PLoS Pathogens*. 2014;10. doi:10.1371/journal.ppat.1003947
- 589 50. Pérez-Mazliah D, Ng DHL, Rosário APF do, McLaughlin S, Mastelic-Gavillet B, Sodenkamp J, et al.
590 Disruption of IL-21 Signaling Affects T Cell-B Cell Interactions and Abrogates Protective Humoral
591 Immunity to Malaria. *PLOS Pathogens*. 2015;11: e1004715. doi:10.1371/journal.ppat.1004715
- 592 51. Leonard WJ, Wan CK. IL-21 Signaling in Immunity. *F1000Research*. 2016;5.
593 doi:10.12688/F1000RESEARCH.7634.1
- 594 52. de Leur K, Dor FJMF, Dieterich M, van der Laan LJW, Hendriks RW, Baan CC. IL-21 receptor
595 antagonist inhibits differentiation of B cells toward plasmablasts upon alloantigen stimulation.
596 *Frontiers in Immunology*. 2017;8: 306. doi:10.3389/FIMMU.2017.00306/FULL
- 597 53. Erman B, Bilic I, Hirschmugl T, Salzer E, Çagdas D, Esenboga S, et al. Combined immunodeficiency
598 with CD4 lymphopenia and sclerosing cholangitis caused by a novel loss-of-function mutation
599 affecting IL21R. *Haematologica*. 2015;100: e216. doi:10.3324/HAEMATOL.2014.120980
- 600 54. Kotlarz D, Zięta N, Uzel G, Weidemann T, Braun CJ, Diestelhorst J, et al. Loss-of-function
601 mutations in the IL-21 receptor gene cause a primary immunodeficiency syndrome. *The Journal*
602 *of Experimental Medicine*. 2013;210: 433. doi:10.1084/JEM.20111229
- 603 55. Stepensky P, Keller B, Abuzaitoun O, Shaag A, Yaacov B, Unger S, et al. Extending the clinical and
604 immunological phenotype of human interleukin-21 receptor deficiency. *Haematologica*.
605 2015;100: e72. doi:10.3324/HAEMATOL.2014.112508

- 606 56. Spolski R, Leonard WJ. Interleukin-21: a double-edged sword with therapeutic potential. *Nature*
607 *reviews Drug discovery*. 2014;13: 379–395. doi:10.1038/NRD4296
- 608 57. Jin H, Carrio R, Yu A, Malek TR. Distinct activation signals determine whether IL-21 induces B cell
609 costimulation, growth arrest, or Bim-dependent apoptosis. *Journal of immunology* (Baltimore,
610 Md : 1950). 2004;173: 657–665. doi:10.4049/JIMMUNOL.173.1.657
- 611 58. Mehta DS, Wurster AL, Whitters MJ, Young DA, Collins M, Grusby MJ. IL-21 induces the apoptosis
612 of resting and activated primary B cells. *Journal of immunology* (Baltimore, Md : 1950).
613 2003;170: 4111–4118. doi:10.4049/JIMMUNOL.170.8.4111
- 614 59. Ozaki K, Spolski R, Ettinger R, Kim H-P, Wang G, Qi C-F, et al. Regulation of B cell differentiation
615 and plasma cell generation by IL-21, a novel inducer of Blimp-1 and Bcl-6. *Journal of immunology*
616 (Baltimore, Md : 1950). 2004;173: 5361–5371. doi:10.4049/JIMMUNOL.173.9.5361
- 617 60. Bockstal V, Guirnalda P, Caljon G, Goenka R, Telfer JC, Frenkel D, et al. *T. brucei* infection reduces
618 B lymphopoiesis in bone marrow and truncates compensatory splenic lymphopoiesis through
619 transitional B-cell apoptosis. *PLoS pathogens*. 2011;7. doi:10.1371/JOURNAL.PPAT.1002089
- 620 61. Cnops J, Kauffmann F, De Trez C, Baltz T, Keirse J, Radwanska M, et al. Maintenance of B cells
621 during chronic murine *Trypanosoma brucei gambiense* infection. *Parasite immunology*. 2016;38:
622 642–647. doi:10.1111/PIM.12344
- 623 62. M B, T O, A L, B H, P VDM, K K. Induction of interferon-gamma, transforming growth factor-beta,
624 and interleukin-4 in mouse strains with different susceptibilities to *Trypanosoma brucei brucei*.
625 *Journal of interferon & cytokine research : the official journal of the International Society for*
626 *Interferon and Cytokine Research*. 1996;16: 427–433. doi:10.1089/JIR.1996.16.427
- 627 63. Franco JR, Cecchi G, Paone M, Diarra A, Grout L, Ebeja AK, et al. The elimination of human
628 African trypanosomiasis: Achievements in relation to WHO road map targets for 2020. *PLoS*
629 *neglected tropical diseases*. 2022;16. doi:10.1371/JOURNAL.PNTD.0010047
- 630 64. Dickie EA, Giordani F, Gould MK, Mäser P, Burri C, Mottram JC, et al. New Drugs for Human
631 African Trypanosomiasis: A Twenty First Century Success Story. *Tropical medicine and infectious*
632 *disease*. 2020;5. doi:10.3390/TROPICALMED5010029
- 633 65. Koné M, Kaba D, Kaboré J, Thomas LF, Falzon LC, Koffi M, et al. Passive surveillance of human
634 African trypanosomiasis in Côte d’Ivoire: Understanding prevalence, clinical symptoms and signs,
635 and diagnostic test characteristics. *PLoS neglected tropical diseases*. 2021;15.
636 doi:10.1371/JOURNAL.PNTD.0009656
- 637 66. “H3Africa Working Group on Ethics and Regulatory Issues for the Human Heredity and Health in
638 Africa (H3Africa) Consortium.” H3Africa Guideline for Informed Consent. 2013
- 639